|
AU2007202911A1
|
|
Methods to enhance white blood cell count
|
|
WO2006138350A2
|
|
Chemokine receptor binding compounds
|
|
TW200619206A
|
|
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
CN101094684A
|
|
Chemokine combinations to mobilize progenitor/stem cells
|
|
KR20060131899A
|
|
Process for the synthesis of a cxcr4 antagonist
|
|
ZA200404589B
|
|
Chemokine receptor binding heterocyclic compounds with enhanced efficacy.
|
|
MXPA05011353A
|
|
Chemokine receptor binding heterocyclic compounds with enhanced efficacy.
|
|
CN1777423A
|
|
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
CA2520259A1
|
|
Cxcr4 chemokine receptor binding compounds
|
|
US7354932B2
|
|
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
US7169750B2
|
|
Methods to mobilize progenitor/stem cells
|
|
ZA200301399B
|
|
Chemokine receptor binding heterocyclic compounds.
|
|
HU0402458A2
|
|
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
NZ531482A
|
|
Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
|
|
CA2455559A1
|
|
Methods to mobilize progenitor/stem cells
|
|
CA2442414A1
|
|
Use of rare earth compounds for the prevention of kidney stone disease
|
|
IL154400D0
|
|
Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
|
|
CN1980916A
|
|
Chemokine receptor binding heterocyclic compounds
|
|
PL359523A1
|
|
Chemokine receptor binding heterocyclic compounds
|
|
MXPA03002327A
|
|
Chemokine receptor binding heterocyclic compounds.
|
